Claims for Patent: 10,278,984

Summary for Patent: 10,278,984

Title:	Guanosine as an immune potentiator mediated through toll receptors
Abstract:	Methods and Compositions involving the administration of guanosine, identified as Toll like receptor (TLR) 2 and 4 agonists, that will be useful for enhancing the potency of vaccine and cancer immunotherapies are disclosed. Method of preventing and treating cancer and infection by administration of guanosine or pro-drugs of guanosine, or a precursor of guanosine are also disclosed. Compositions of guanosine or a pro-drug of guanosine or precursor of guanosine may be formulated as pharmaceutical dosage forms and components can be assembled as kits. Methods for activating TLRs with guanosine to enhance an immune response and to potentiate/augment antiviral, antibacterial or anticancer effects of other antiviral, anti-bacterial and anticancer therapeutic agents are also disclosed.
Inventor(s):	Bantia; Shanta (Birmingham, AL)
Assignee:	Nitor Therapeutics (Birmingham, AL)
Application Number:	15/306,876
Patent Claims:	1. A method for enhancing the potency of a vaccine or an immunotherapy in a subject, the method comprising: administering a pharmaceutically effective amount of guanosine to the subject in conjunction with the vaccine or immunotherapy. 2. The method according to claim 1, wherein the method comprises enhancing the potency of a vaccine or an immunotherapy administered for the treatment of a cancer, bacterial infection, or viral infection. 3. The method according to claim 1, wherein the immunotherapy comprises administration of one or more immunotherapeutic agents selected from checkpoint protein modulators, Indoleamine-pyrrole 2,3-dioxygenase inhibitors, and Toll like receptor (TLR) agonists. 4. The method according to claim 3, wherein the checkpoint protein modulator is selected from the group consisting of cytotoxic T-lymphocyte-associated protein 4(CTLA-4) antagonists, glucocorticoid-induced tumor necrosis factor related protein (GITR) agonists, tumor necrosis factor receptor superfamily member 4 (OX40) agonists, Lymphocyte Activation Gene-3 (LAG-3) antagonists, T cell immunoglobulin and mucin domain-3 (TIM-3) antagonists and Programmed Death-1 (PD-1) antagonists, Programmed Death Ligand-1 (PDL-1) antagonists and CD-27 agonists. 5. The method according to claim 3, wherein the checkpoint protein modulator is selected from the group consisting of CTLA-4 antagonist ipilimumab, PD-1 antagonist pembrolizumab and nivolumab. 6. The method according to claim 3 wherein the TLR agonist is selected from the group consisting of TLR7 agonist imiqimod, GS-9620, TLR7/8 agonist resiquimod, and TLR9agonists. 7. The method according to claim 1 wherein administering is via an enteral or parenteral or topical route.

Details for Patent 10,278,984

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011		2039-05-25
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	For Injection	125514	09/04/2014		2039-05-25
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	Injection	125514	01/15/2015		2039-05-25
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	12/22/2014		2039-05-25
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	10/04/2017		2039-05-25
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	08/27/2021		2039-05-25